YANTAI, China--(BUSINESS WIRE)--Bohai Pharmaceuticals Group, Inc. (OTCBB/OTCQB: BOPH), a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, today announced revenue and earnings guidance for its fiscal year ending June 30, 2010. Based on a preliminary assessment of Bohai’s year-end financials, which will be finalized toward the end of September and announced through a 10-K filing with the SEC, Bohai expects to report record levels of net revenue and net income in comparison to its fiscal 2008 and 2009 results.
